Mallinckrodt (MNK) Reports Complete Enrollment Target for Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)
Tweet Send to a Friend
Mallinckrodt plc (NYSE: MNK) today announced it has completed enrollment of the company's ongoing Phase 4 clinical trial of H.P ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
